Drug intelligence / Profile preview

XmAb 2513

Development stage: Phase 1
Lead developer: Xencor
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

XmAb 2513 is a humanized monoclonal antibody developed to target the CD30 antigen, which is expressed on the surface of several tumor cell types, notably in Hodgkin lymphoma and anaplastic large cell lymphoma. The drug was engineered using Xencor's Fc-engineering technology to enhance its binding affinity for FcγRIIIA receptors, resulting in increased antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) compared to non-engineered antibodies. Its mechanism involves direct anti-proliferative effects on CD30-positive cells as well as immune-mediated cytotoxicity. XmAb 2513 was primarily developed by Xencor for use in hematologic malignancies such as Hodgkin lymphoma and T-cell lymphomas[1][4][5][6][8].

Other names: XmAb™2513

Targets

CD30 (CD30 antigen)

Beyond the preview

Go deeper on XmAb 2513.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XmAb 2513.

Explore the full profile